Cipla Announces Launch of Leuprolide Acetate Injection Depot (22.5mg)

Cipla announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the US FDA based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway.